Literature DB >> 8344487

Interaction of adenoviral proteins with pRB and p53.

E Moran1.   

Abstract

The transforming gene products of the small DNA tumor viruses subvert host cell growth control mechanisms by binding to specific cell regulatory proteins. These include the retinoblastoma gene product (pRB) and p53. One indication of the pivotal roles played by these regulatory products is the observation that they are each targeted consistently by viruses of several groups, by adenoviruses, the human papillomaviruses, and the papovaviruses. In adenovirus, pRB and p53 are targeted by the E1A and E1B genes, respectively. The genetic probes made possible by manipulation of the virus genes in vitro have helped to illuminate the pathways in which pRB and p53 function. E1A studies have contributed to our current understanding that the retinoblastoma product is one of a family of related proteins, which with associated cyclins and kinases can modulate the activity of the cellular E2F transcription factor. E1B studies have helped explore models of p53 function, including the suggestion that p53, probably through aspects of its transcription regulating activity, can initiate a pathway in which programmed cell death can be invoked to stop unrestricted cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8344487     DOI: 10.1096/fasebj.7.10.8344487

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  46 in total

Review 1.  DNA replication and cell cycle in plants: learning from geminiviruses.

Authors:  C Gutierrez
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

2.  E1A blocks hyperphosphorylation of p130 and p107 without affecting the phosphorylation status of the retinoblastoma protein.

Authors:  M Parreño; J Garriga; A Limón; X Mayol; G R Beck; E Moran; X Graña
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Stimulation of the cell cycle and maize transformation by disruption of the plant retinoblastoma pathway.

Authors:  William Gordon-Kamm; Brian P Dilkes; Keith Lowe; George Hoerster; Xifan Sun; Margit Ross; Laura Church; Chris Bunde; Jeff Farrell; Patrea Hill; Sheila Maddock; Jane Snyder; Louisa Sykes; Zhongsen Li; Young-min Woo; Dennis Bidney; Brian A Larkins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-16       Impact factor: 11.205

4.  E1A and E1B proteins inhibit inflammation induced by adenovirus.

Authors:  Jerome Schaack; Michael L Bennett; Jeff D Colbert; Andres Vazquez Torres; Gerald H Clayton; David Ornelles; John Moorhead
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

5.  Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells.

Authors:  K C Thome; A Radfar; N Rosenberg
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Genetic identification of adenovirus type 5 genes that influence viral spread.

Authors:  T Subramanian; S Vijayalingam; G Chinnadurai
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  Nucleoplasmic and nucleolar distribution of the adenovirus IVa2 gene product.

Authors:  P Lutz; F Puvion-Dutilleul; Y Lutz; C Kedinger
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  A novel E1A domain mediates skeletal-muscle-specific enhancer repression independently of pRB and p300 binding.

Authors:  A Sandmöller; H Meents; H H Arnold
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  Simian virus 40 small T antigen activates AMPK and triggers autophagy to protect cancer cells from nutrient deprivation.

Authors:  Sravanth Hindupur Kumar; Annapoorni Rangarajan
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control.

Authors:  S R Bartz; M E Rogel; M Emerman
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.